Poor Indoor Air Quality Exposure and Clinical Risks with Edward Brooks, MD, and Charlene McEvoy, MD

Podcast

The pair of pulmonology and microbiology experts join the podcast to discuss what clinicians should look out for in indoor pollutant exposure risks, and how to manage their impact.

Episode highlights

0:16 The history of indoor air environments
2:50 Introducing Edward G. Brooks, MD, and Charlene McEvoy, MD
4:39 The factors of poor indoor air quality
6:25 Ways to improve indoor air quality
8:59 The underlying pathophysiology of pollutants
13:02 Benzene recalls
14:18 High-risk behaviors and disease risks
17:14 Recommendations for exposed patients
21:02 Radon as a lung cancer risk
22:35 Final thoughts
25:42 Outro

An unforeseen consequence of isolation and quarantine in response to reduce COVID-19 exposure risk has been the increased exposure to indoor air pollutants and poor indoor environments.

In fact, as allergists have explained to HCPLive, many patients have commonly misinterpreted emerging allergy exposure symptoms as COVID-19 symptoms. It’s an entirely different risk for clinicians to identify and help provide care for.

In the latest episode of Lungcast, a pair of experts join American Lung Association (ALA) chief medical officer Albert Rizzo, MD, to discuss how these risks manifest and how they can be mitigated by patients and clinicians alike.

Edward G. Brooks, a professor in Microbiology, Immunology & Molecular Genetics at the University of Texas San Antonio and Charlene McEvoy, MD, a pulmonologist and assistant professor of Medicine at the University of Minnesota, headline the comprehensive discussion into indoor air quality health.

Rizzo, Brooks, and McEvo also review the recent recall of benzene exposure-risk products in the dry shampoo industry, as well as navigating issues without other carcinogens including radon exposure.

Lungcast is a monthly respiratory health podcast series from the ALA produced by HCPLive.

Subscribe or listen to Lungcast on your favorite platforms:

Related Videos
A Promising Pipeline for COPD
Projecting Dupilumab's Fit in COPD
What the Ensifentrine FDA Approval Means for COPD
Pavel Strnad, MD | Credit: RWTH Aachen
Caroline Sisson, MMS, PA-C: Updates in Pulmonary Function Testing
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
What Should the American Academy of Physician Associates Focus on in 2025?
© 2024 MJH Life Sciences

All rights reserved.